Investors should buy the dip on this pharma stock with 40% upside, Truist says

Truist Securities initiated coverage of Teva Pharmaceutical with a buy rating and a $25 price target, implying a 41% upside, citing the company's durable growth strategy and margin improvement initiatives. The firm highlights Teva's focus on high-margin specialty brands, manufacturing optimization, and its continued strength in generics, anticipating further details at the upcoming Innovation and Strategy Day on May 29. Teva shares rose over 1% following the report, with a consensus of analysts also showing optimism for the stock.

Analysis

Truist Securities has initiated coverage on Teva Pharmaceutical (TEVA) with a buy rating and a $25 price target, suggesting a significant 41% upside potential from current levels. This optimistic outlook comes despite Teva's shares declining approximately 20% year-to-date, a pullback Truist views as a buying opportunity. The rationale for the buy rating centers on Teva's long-term durable growth strategy and focused margin improvement initiatives, including the "Pivot to Growth" plan introduced in 2023, which targets a potential 300 basis point operating margin improvement by 2027. Key drivers for this improvement include the performance of high-margin specialty brands like Austedo and Ajovy, and a strategic reduction in manufacturing facilities from 34 to under 22. Truist also highlighted Teva's continued strength as a "generics powerhouse," benefiting from new product launches and portfolio optimization, alongside an innovative drug pipeline featuring olanzapine and duvakitug. The market reacted positively, with Teva shares gaining over 1% following the announcement. This sentiment aligns with broader analyst consensus, as LSEG data shows eight out of eleven analysts covering Teva rate it a buy or strong buy, with an average price target indicating nearly 29% upside. Investors anticipate further details on Teva's growth trajectory during its upcoming Innovation and Strategy Day on May 29, where management is expected to unveil an updated 5-year outlook.

Key Decisions for Investors

• Consider accumulating Teva shares, given the analyst's view of the recent 20% YTD pullback as an attractive entry point ahead of potential significant upside.
• Closely monitor Teva's Innovation and Strategy Day on May 29 for management's updated 5-year outlook and further details on its "Pivot to Growth" strategy, which could serve as a key catalyst.
• Evaluate Teva's progress on its margin improvement targets, particularly through manufacturing optimization and the performance of its high-margin specialty brands, as these are critical to realizing the projected growth.